The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa).
 
Xiaojie Bian
No Relationships to Disclose
 
Dingwei Ye
No Relationships to Disclose
 
Lijun Chen
No Relationships to Disclose
 
Changlu Hu
No Relationships to Disclose
 
Shusuan Jiang
No Relationships to Disclose
 
Nianzeng Xing
No Relationships to Disclose
 
Qingyun Zhang
No Relationships to Disclose
 
Shuang Zhang
No Relationships to Disclose
 
Jimin Chen
No Relationships to Disclose
 
Fan Cheng
No Relationships to Disclose
 
Guiling Li
No Relationships to Disclose
 
Bin Hu
No Relationships to Disclose
 
Gongxian Wang
No Relationships to Disclose
 
Haitao Niu
No Relationships to Disclose
 
Hui Chen
No Relationships to Disclose
 
Jinjian Yang
No Relationships to Disclose
 
Peng Zhang
Employment - Abbisko Therapeutics Co.,Ltd
 
Quan Yuan
Employment - Abbisko Therapeutics Co.,Ltd
 
Xi Gu
Employment - Abbisko Therapeutics Co.,Ltd
 
Yichao Chen
Employment - Abbisko Therapeutics Co.,Ltd